Glaxo socks more cash into immunotherapy bet

Last year, GlaxoSmithKline ($GSK) traded away most of its cancer assets to Novartis ($NVS) in exchange for the majority of the Swiss drugmaker's vaccines portfolio. But it's not out of the area altogether, and now, it's sweetening a deal with oncology partner Adaptimmune. Glaxo has promised more cash to speed up development of a promising treatment for soft tissue sarcoma, pledging to fund pivotal trials for the immunotherapy. Read more from FierceBiotech

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.